| Drug Name | Binocrit®(Epoetin Alfa) |
|---|---|
| Drug Class |
Hematopoietic growth factor
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Hematology
|
| Risk |
neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception, in Tsepamo Study, Botswana |
| Dear Healthcare provider letter DHPC |
|